Monday, June 27, 2005

Dr O'Reilly June 27 05

June 27, 2005
British of Columbia Ministry of Health Services
RE; Renee Dueck

Dear Sirs/Madams:
I am writing to request medical insurance coverage for Renee Dueck, a 21 -year-old Caucasian female from Manitoba who has recently been diagnosed with an M2 morphology acute myelogenous leukemia. This patient is a unique patient in that she was born with an autosomal form of severe combined immune deficiency and received an HLA haplotype disparate T cell depleted transplant from her mother after conditioning with busulfan and cyclophosphamide on July 26, 1984. This transplant resulted in durable engraftment of maternal lymphoid elements, both T cells and B Lymphocytes with full reconstitution of both T cell, mediated and antibody-mediated immunity.

She did not develop any graft vs. host disease. Thereafter, she enjoyed normal growth and development, without significant infections. The current state of myeloid chimerism at this time is not known. However, in all previous studies, the antigen responsive T and B cells in this child are maternal in origin. Her most recent assessment of T cell function dates to one month ago at which time she had a full complement of normally distributed T lymphocytes and normal responses to mitogens and antigens.

Over the last 2 weeks the patient developed a cellulitis of the legs as welt as multiple ecchymoses on the legs. At this time, she sought a medical evaluation at the Strongsville Division of the Cleveland Clinic, and was seen by Dr. Shawn He. She was noted to be severely neutropenic with a neutrophit count less than 500 mm with normal platelets. A marrow aspirate and biopsy performed by Dr. He demonstrated a marrow containing 32 % myeloid blasts, M2 type by morphology and by immunophenotype.

The patient will clearly need appropriate treatment for her acute myelogenous leukemia. The special circumstances of this child are such that accurate diagnosis of her disease is imperative. First, it is important that we ascertain the cell of origin of the leukemia. The patient was cytoreduced in 1984 with busulfan and cyclophosphamide. As a result there is the possibility of developing a late secondary

hematologic malignancy in her own cells. At this stage after the transplant, this would be rare since secondary leukemias, if they occur, usually develop within 15 years of the treatment. Nevertheless, this is the most likely possibility. In this case, it would be anticipated that the myeloid progenitor cells are derived from the patient. ALternatively, it is possible that the myeloid leukemia has evolved from the blood forming cells derived from the patient’s mother. The mother is healthy and hematologically normal. She is aLso HLA haplotype disparate from her daughter.

The implications in terms of treatment are quite important. If this AML has attributes of a chemotherapy associated secondary leukemia, it must be considered a high risk form of the disease. Such an AML would be appropriately treated with aggressive induction therapy with daunomycin and cytosirte arabinoside, possibly also including VP-16 and thioguanine since the DOCTER regimen has been associated with a particularly higher likelihood of sustained remission. An alternative regimen, potentially including only the daunomycin and ARA-C, could be considered for a primary AML. The treatment options for subsequent therapy also clinically depend upon these initial evaluations. If the patient has a secondary AML in her own hematopoietic cells, a transplant in first remission is clearly the treatment of choice. In this case the patient does not have an HLA matched sibling. However, the patient is durably engrafted with a lymphoid system that is entirely derived from her mother who is HLA A, B, DR disparate. For a transplant, we would propose to give a secondary graft after suitable cytoreduction from the mother who is the original donor.

A use of any other donor potentially matched to the patient entails a major risk of graft rejection by residual fully functional T cells derived from the haplotype disparate mother as well as the risk of a potentially lethal graft vs. host disease due to the fact that there are enough antigen presenting cells of maternal origin in this child to permit the stimulation of allo-reactive donor cells and subsequent generation of a lethal graft vs. host in the post transplant period. If the mother’s graft is used, a T cell depleted graft would be the only option. However, cytoreduction could be selected to maximize antileukemic effects, since the risk of the mother’s own T cells, already resident in the child, rejecting the grafts is minimal. Our studies here since 1980 have demonstrated no increase in the risk of leukemic relapse following a transplant for AML either in primary or secondary AMLs when a T cell depleted graft administered after myeloablative cytoreduction has been administered.

We would propose to have her come to Memorial Sloan-Kettering Cancer Center. Diagnostic marrows will be obtained. We will attempt to isolate, culture and identify the cell of origin of her AML. She will also have studies performed to determine her current state of chimerism, specifically to determine the origin of her T cells, B cells and normal progenitor cells. She could then be induced with a chemotherapeutic regimen. This could be started here at MSKCC and potentially maintained at home in Winnipeg.

I do feel, however, that if her disease warrants a transplant (at this point I expect that it will) that the transplant be performed at MSKCC because of our special expertise in transplants of HLA haplotype disparate T cell depleted marrow transplants, particularly for the treatment of severe combined immune deficiency and for leukemic disorders, The issues here are absolutely unique in the experience for severe combined immune deficiency. To my knowledge this is the first case of any leukemia occurring in SCID late after a transplant procedure. More importantly the unique chimeric state of this patient entails a significant number of difficult choices in the selection of treatment, transplant, cytoreduction and the type of transplant administered.
I would be happy to discuss this case further with you at any time. I urge your approval for insurance coverage for this unique patient so that we can define her disease adequately so as to be able to plan a potentially curative approach for this unique and potentially high-risk form of AML

Thank you for your consideration.
Sincerely yours,
Richard J. O MD
Chairman, Department of Pediatrics
Chief, Bone Marrow Transplantation Program
Memorial Sloan-Kettering Cancer Center

Renee is feeling good

Date: Mon, 27 Jun 2005 08:12:03 -0500 [06/27/2005 08:12:03 AM CDT]
From: Raymond Dueck Subject: Renee's treatment
Thanks for praying.
Renee is feeling good. The swelling in her legs has pretty much dissappeared. We are not sure at this point what the next step is. Dr O'Reilly would like to see her in NYC. It would be nicer if the treatment could be done at home. We have not yet heard from the Winnipeg doctors. Can they do the necessary procedures there? Will they give a letter to MB Health to authorize coverage at NYC?
We are sitting here waiting for answers.
Renee appreciates your phone calls at 216-444-1303
Raymond Dueck

Sunday, June 26, 2005

from Cleveland Clinic

Date: Sun, 26 Jun 2005 16:06:07 -0500
From: Raymond Dueck
We were referred to you by Dr Bob Friesen and by Sharon Boychuk Our daughter, Renee, had SCIDS and received a bone marrow transplant in NYC at MSKCC under Dr Richard O'REILLY 21 years ago. This year she was on tour in the US and suffered several occasions of swelling/bruising on her legs. On Tuesday she dropped in to a Cleveland Clinic. They did blood tests and bone marrow aspirations and determined that she has acute myelogenous leukemia. She was admitted to hospital on Friday. Her doctor here is Brad Pohlman, M.D. a member of the transplant team
Cleveland Clinic may be a good hospital but Winnipeg is home for us. What complicates the situation is her unmatched bone marrow transplant when she was a baby. Dr O'Reilly's team did a stem cell transplant using bone marrow from her mother. Dr O'Reilly feels that the safest place to treat her is at Memorial in NYC. We expect to fly to NYC with her on Monday.
If you and Dr O'Reilly could agree that the chemo therapy could be done in Winnipeg, then we would return with her as soon as Dr O'Reilly gives the go-ahead.
If you agree that MSKCC is the right place for her to get the best treatment, we will need a letter from you to Manitoba Health to that effect, so that they will pick up most of the tab for the treatment.
Dr O'Reilly can be contacted at O'Reilly, Richard J. Chairman, Department of Pediatrics; Chief, Pediatric Bone Marrow Transplant Service; Claire L. Tow Chair in Pediatric Oncology Research (212) 639-5957
Your time and effort is much appreciated.
On behalf of Renee
Raymond & Martha Dueck

Saturday, June 25, 2005

This is the 1st email

From: Raymond Dueck
To: Undisclosed-Recipient:;
Sent: Friday, June 24, 2005 11:52 PM
Subject: Renee is in hospital
She was admitted today at Cleveland Clinic Foundation in Cleveland with acute leukemia our flight leaves at 7 a.m. Saturday morning we have no idea when we will be back please pray for her and God's hand of healing on her and wisdom for her doctors
Renee has been admitted to
Her doctor is Anjali Advani, M.D.
She is on intravenous antibiotics
The phone # at her bedside is 216-444-1303
Your prayers are much appreciated!
Raymond & Martha Dueck
2 Eagle Court
East St Paul MB R0E 0L2
cell 204-782-2112
Martha's cell 204-771-7559
204-364-2454 fax
Check out
Quoting Ken and Carolee Neufeld
Dear Friends,
Please pray...
Today I was on a day trip with a friend, Ray Dueck, a business man and president of LifeLight Ministries. A call came on his cell phone that no dad wants to receive. His daughter Renee had just been diagnosed with acute leukemia. It was the doctor calling. Renee is 21 years old and is on a YWAM (Youth With A Mission) team. At this time the team was in CLEVELAND, on an itinerary in the US. We receive Renee's news letters and it is evident that she is passionate about serving Jesus.
Ray and Martha will be on a flight at 7am, Saturday, to be with their daughter and to arrange medical treatment in New York. Please take a moment to pray for Renee and her family. If the Lord places them on your heart, continue with us in prayer for them.
Living Free Ministries
732 McMillan Avenue
Winnipeg, Manitoba
R3M 0V2
(204) 284-1973